S18 Ep19: Navigating Fixed-Durations Regimens in CLL and Improving Outcomes for High-Risk Patients: With John N. Allan, MD
In today’s episode, we spoke with John N. Allan, MD. Dr Allan is an associate attending physician at New York-Presbyterian Hospital and an associate professor of clinical medicine at Weill Cornell Medical College in New York, New York.
In our exclusive interview, Dr Allan discussed his review of the currently approved fixed-duration regimens for chronic lymphocytic leukemia (CLL). Regimens like venetoclax (Venclexta) plus obinutuzumab (Gazyva), ibrutinib (Imbruvica) plus venetoclax, acalabrutinib (Calquence) plus venetoclax, and venetoclax plus rituximab (Rituxan) were all regimens that Allan…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.